While Australia Watches the Big Healthcare Deals, the Real Action Is in the Clinics Nobody's Covering.

A$2.5 billion. That's the headline number attached to Bain Capital's exit of Estia Health to Stonepeak, announced in February 2026, and it's the kind of figure that dominates healthcare M&A coverage. Add in Sigma Healthcare's merger with Chemist Warehouse and the ongoing radiology auction involving Qscan, Perth Radiological Clinic and several other clinical trial and imaging assets, and it's easy to conclude that Australian healthcare M&A is a story about scale: big platforms, big infrastructure-style capital, big multiples.

It isn't. Or rather, it's only half the story, and it's the less interesting half if you're a lower mid-market investor.

The mega-deals are a symptom, not the opportunity

The large transactions making headlines share a common thread: they're the endpoint of consolidation cycles that started years, sometimes a decade, earlier, often in unglamorous corners of the sector. Estia's aged care platform, the dental networks built by groups like Pacific Smiles and Maven Dental, the physiotherapy and podiatry consolidation that produced Healthia, all began as fragmented networks of founder-owned practices before institutional capital arrived to scale them.

That earlier phase, the one happening right now in allied health, dental, GP clinics and diagnostics, is where the founder-owned asset still trades at a fraction of platform value. According to Miro Capital, individual practices in these categories are still being acquired at roughly 5 to 7 times EBITDA, while the consolidated platforms built from them are valued by institutional buyers at 10 to 15 times. That gap is the lower mid-market opportunity, and it's largely absent from the coverage chasing billion-dollar exits.

Capital is already moving, quietly

It isn't as though sophisticated buyers have missed this. Next Capital's roughly $100 million commitment to allied health roll-up InterHealthcare, reported by Street Talk, began with the acquisition of 35 multi-disciplinary practices turning over more than $30 million combined, and set out an explicit ambition to scale toward 70 clinics. Pacific Equity Partners has taken a similar path with Healthia, now operating more than 320 clinics and over 1,100 clinicians nationally.

These are not headline deals. They rarely make the front page of the financial press, and that's precisely the point. The lower mid-market roll-up thesis in allied health, dental and diagnostics has been quietly compounding while attention stays fixed on the Estias and Sigmas of the world.

The regulatory backdrop has changed, and that changes who wins

What's genuinely new, and underappreciated, is regulation. Australia's mandatory merger notification regime, effective from 1 January 2026 under the revised Competition and Consumer Act, explicitly captures serial roll-ups in dental, GP, pathology, imaging and allied health, according to analysis from CT Acquisitions. Every bolt-on now carries a notification obligation regardless of individual deal size, a direct response to regulatory concern about "creeping acquisitions" in fragmented healthcare categories.

For large, well-resourced platforms with in-house legal and compliance functions, this is a manageable cost of doing business. For smaller, thinly capitalised roll-up vehicles trying to move fast and acquire dozens of practices in quick succession, it's friction that slows the aggressive land-grab model down considerably. That shift favours disciplined, patient lower mid-market buyers over speed-driven consolidators, a dynamic that hasn't yet been priced into how founders think about who to sell to.

There's a second structural shift worth acknowledging honestly: credit has tightened materially across healthcare leveraged buyouts following the collapse of Healthscope, Australia's largest private hospital operator, with sponsor equity contributions on aged care and hospital deals now running 50 to 55 percent of enterprise value versus the 35 to 40 percent that was typical through 2021 and 2022, per CT Acquisitions. Lower mid-market allied health and dental transactions were rarely underwritten on that kind of leverage to begin with, which means this reset affects large-cap sponsors far more than it affects disciplined buy-and-build strategies already running on conservative equity contributions.

What this means for founders and operators

If you're a founder of a multi-clinic allied health, dental or diagnostics business in Australia or New Zealand today, the calculus has shifted twice over. The multiple gap between standalone practice and consolidated platform hasn't closed, and a tighter regulatory environment now rewards buyers who build carefully rather than those racing to scale before scrutiny catches up. The businesses likely to command genuine platform premiums at exit won't be the ones assembled fastest. They'll be the ones assembled by partners who treated each notification obligation, each clinical governance question and each staff retention plan as part of the value creation thesis rather than a compliance afterthought.

That's a different kind of opportunity than the one implied by billion-dollar headlines, and it's one that rewards patience over pace.

By Astra Capital

Let's talk

If you're building or operating a founder-led healthcare, allied health or diagnostics business in Australia, New Zealand or Southeast Asia and you're thinking through what the next stage of growth or ownership looks like, we'd welcome the conversation.

Sources

• Miro Capital, Healthcare Practice Valuations in Australia
• Street Talk / Next Capital, Next Capital commits $100m to fuel allied health pioneer
• Pacific Equity Partners, Healthia investment profile
• CT Acquisitions, The Australia PE Buyer Landscape 2026
• ION Analytics, Australian M&A holds firm in 1H26 despite shelved mega-deals

This article is provided for general informational purposes only and does not constitute financial, investment, legal or tax advice, nor an offer, solicitation or recommendation in respect of any security, fund or transaction. Views expressed are those of Astra Capital Proprietary Limited ACN 691553849 at the time of publication and may change without notice. Information sourced from third parties is believed to be reliable but has not been independently verified and no warranty is given as to its accuracy or completeness. Past performance and industry trends are not indicative of future results. Readers should seek independent professional advice before making any investment decision. © Astra Capital Proprietary Limited ACN 691553849. All rights reserved.